Table 1.

Included ADCs with linker type, drug-to-antibody ratio, and systemic maximum free payload concentration

Antibody drug conjugate	Indication(s)	Antigen	Payload agent	Number of studies	Number of patients	Linker	Drug-to-antibody ratio (DAR)	Systemic maximum free payload concentration (kg/L)
Belantamab mafodotin	Multiple myeloma	BCMA	MMAF	1	97	Non-cleavable	4	0.0004
Brentuximab vedotin	Hodgkin lymphoma, anaplastic large cell lymphoma, CD30 + peripheral T cell lymphoma, CD30 + mycosis fungoides	CD30	MMAE	11	660	Cleavable	4	0.0026
Enfortumab vedotin	Urothelial cancer	Nectin-4	MMAE	3	515	Cleavable	3.8	0.0040
Gemtuzumab ozogamicin	Acute myeloid leukemia	CD33	Calichea-micin	2	175	Cleavable	2.5	0.0229
Inotuzumab ozogamicin	Acute lymphoblastic leukemia	CD22	Calichea-micin	2	205	Cleavable	6	0.0556
Loncastuximab tesirine	Large B-cell lymphoma	CD19	PBD dimer	1	145	Cleavable	2.3	0.0003
Moxetumomab pasudotox	Hairy cell leukemia	CD22	PE38	1	80	Cleavable	1	No systemic accumulation observed
Sacituzumab govitecan	Breast cancer Urothelial cancer	Trop-2	SN38	3	479	Cleavable	7.6	0.0120
Tisotumab vedotin	Cervical cancer	Tissue factor	MMAE	2	156	Cleavable	4	0.0026
Trastuzumab deruxtecan	Breast cancer Gastric cancer	HER2	Deruxtecan	3	570	Cleavable	8	0.4347
Trastuzumab emtansine	Breast cancer	HER2	Emtansine	12	4,797	Non-cleavable	3.5	0.0012

BCMA B-cell maturation antigen, MMAE monomethyl auristatin, MMAF monomethyl auristatin F, PBD pyrrolobenzodiazepine, PE38 the 38 kDa fragment of Pseudomonas exotoxin A, SN38 active metabolite of irinotecan